Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Ana Sayfa / Yayınlar / Detay

SCI-Expanded Özgün Makale Scopus

American Association for the Advancement of Science (AAAS) 2022 Cilt 7 Sayı 72

Scopus Eşleşmesi Bulundu

Atıf

Cilt

🔓

Açık Erişim

Scopus Yazarları: Jamin Liu, Sara E. Vazquez, Lucy Bizien, Emilie Catherinot, Andrew Willmore, Anthea M. Mitchell, Rebecca Bair, Heather Kenney, Jeremy Manry, Lucie Roussel, Luis Felipe Reyes, Margaux Garzaro, Irene Cassaniti, Fabienne Venet, Anastasiia Bondarenko, Antonio Novelli, Marine Lhuillier, Paul Le Turnier, Adrian Gervais, Quentin Philippot, Maria Salagianni, Garyphallia Poulakou, Eleni Siouti, Günter Weiss, Donald C. Vinh, David Boutboul, Alessandro Borghesi, Anna Aliberti, Guillaume Monneret, Alenka Gagro, Mathilde Neuville, Antonin Bal, Giuseppe Novelli, Kahina Saker, Oana Ailioaie, Gemma Rocamora-Blanch, Carla Teixeira, Clarisse Delaunay, Matthieu Mahevas, Hassan Abolhassani, Guy Gorochov, Laurent Abel, Paul Bastard, Pierre Garçon, Arnaud Fekkar, Sabina Sahanic, Virginia Quaresima, Yacine Tandjaoui-Lambiotte, Bénédicte Neven, Arnau Antolí, Eric Jeziorski, Yu Zhang, Karim Dorgham, Carlos Rodriguez-Gallego, Aurora Pujol, Luis M. Allende, Tayfun Ozcelik, Luisa Imberti, Jesus Troya, Xavier Solanich, Anne Puel, Michael R. Wilson, Matthew T. Laurie, Chung Yu Wang, Tom Le Voyer, Colin Zamecnik, Jérémie Rosain, Ivan Tancevski, Laurenz Nagl, Sotirija Duvlis, Daniel Arroyo-Sánchez, Estela Paz Artal, Luis Rubio, Cristiano Perani, Michela Bezzi, Alessandra Sottini, Nevin Hatipoglu, Rabih Halwani, Narjes Saheb Sharif-Askari, Jeffrey Danielson, Sonia Burrel, Caroline Morbieu, Yurii Stepanovskyy, Alla Volokha, Oksana Boyarchuk, Sevgi Keles, Romain Hernu, Qiang Pan-Hammarström, Thierry Bompoil, Cédric Laouenan, Lisa F.P. Ng, Laurent Renia, Alexandre Belot, François Raffi, Javier Martinez-Picado, Luigi Notarangelo, Shen Ying Zhang, Sophie Trouillet-Assant, Emmanuelle Jouanguy, Chun Jimmie Ye

Özet

Life-threatening "breakthrough"cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-a2 and IFN-w, whereas two neutralized IFN-w only. No patient neutralized IFN-b. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.

Scopus Sayfasını Aç